, Columnist
Sanofi and Regeneron's Price Gamble Is Worth It
Price concessions on Praluent may be the only way the cholesterol drug can crack the market.
This article is for subscribers only.
When drug companies talk about the Institute for Clinical and Economic Review (ICER), an independent organization that gauges the value of prescription drugs, it's usually to push back against it. After all, the ICER often suggests drugs are priced substantially higher than their clinical and economic value.
But Sanofi and Regeneron Pharmaceuticals Inc. made a surprising overture of friendship to the ICER on Saturday. The companies announced they would discount their cholesterol drug Praluent to levels the ICER suggested in a recent analysis for some patients. The announcement came alongside new data showing the medicine substantially reduced the risk of cardiovascular events in high-risk patients.